Bosulif — Revenues:
Pfizer Bosulif — Revenues: decreased by 19.9% to $129.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 14.6%, from $151.00M to $129.00M. Over 4 years (FY 2021 to FY 2025), Bosulif — Revenues: shows an upward trend with a 3.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market share or expanded clinical utilization for the drug, while a decrease may signal increased competition, patent expiration, or shifts in treatment guidelines.
Detailed definition
This metric represents the total net sales generated from the specific oncology pharmaceutical product line. It reflects...
Peer comparison
Comparable to revenue metrics for specific branded oncology assets at other large-cap pharmaceutical companies, often evaluated against therapeutic area growth benchmarks.
pfe_segment_bosulif_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $136.00M | $136.00M | $145.00M | $128.00M | $156.00M | $141.00M | $150.00M | $150.00M | $154.00M | $160.00M | $182.00M | $145.00M | $167.00M | $161.00M | $171.00M | $151.00M | $149.00M | $150.00M | $161.00M | $129.00M |
| QoQ Change | — | +0.0% | +6.6% | -11.7% | +21.9% | -9.6% | +6.4% | +0.0% | +2.7% | +3.9% | +13.8% | -20.3% | +15.2% | -3.6% | +6.2% | -11.7% | -1.3% | +0.7% | +7.3% | -19.9% |
| YoY Change | — | — | — | — | +14.7% | +3.7% | +3.4% | +17.2% | -1.3% | +13.5% | +21.3% | -3.3% | +8.4% | +0.6% | -6.0% | +4.1% | -10.8% | -6.8% | -5.8% | -14.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's bosulif — revenues:?
- Pfizer (PFE) reported bosulif — revenues: of $129.00M in Q1 2026.
- How has Pfizer's bosulif — revenues: changed year-over-year?
- Pfizer's bosulif — revenues: decreased by 14.6% year-over-year, from $151.00M to $129.00M.
- What is the long-term trend for Pfizer's bosulif — revenues:?
- Over 4 years (2021 to 2025), Pfizer's bosulif — revenues: has grown at a 3.1% compound annual growth rate (CAGR), from $540.00M to $611.00M.
- What does bosulif — revenues: mean?
- The total revenue generated from sales of the Bosulif oncology medication.